Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
A phase 2 trial of Relmacabtagene autoleucel, Fludarabine, Cyclophosphamide in follicular lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting.
Overview
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL is a phase 2 interventional study registered as NCT06093841 by Shanghai Ming Ju Biotechnology Co., Ltd., with 46 participants planned, started 2023-11-03 and due to reach its primary completion in 2024-01-21. Interventions recorded: Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide. Conditions listed: Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
Shares Relmacabtagene autoleucel, JW Therapeutics.
- TrialRELIANCE
Shares Relmacabtagene autoleucel, JW Therapeutics.
- TrialStudy of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
Shares Fludarabine, Cyclophosphamide, Follicular lymphoma.
- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.